INN or brand name drug prescriptions: a multilevel, cross-sectional study in general practice.


Journal

European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 19 08 2018
accepted: 19 10 2018
pubmed: 29 10 2018
medline: 10 5 2019
entrez: 29 10 2018
Statut: ppublish

Résumé

The prescription in International Nonproprietary Names (INN) is a legal obligation for all physicians in France since January 2015. The objective of this study was to analyze the frequency and main factors of INN drug prescribing in general practice. Multicenter cross-sectional study conducted with 11 interns acting as observers of 23 GP trainers between November 2015 and January 2016. Two evaluators analyzed all GPs' drug prescriptions to identify INN or brand name prescriptions. The database included 4957 drugs prescribed during 1647 visits. Of these, 1462 (29.5% [95% CI 28.2-30.8%]) were prescribed only in INN. According to the multivariate analyses, the factors favoring INN prescribing were as follows: at the drug level, its initial prescribing (OR = 1.4), a nonspecific prescribing objective (OR = 1.6), its listing in the generic drug index with (OR = 7.7) or without (OR = 2.9) efficiency objective included in the payment for public health objectives (PPHO) program, and the oral route of administration (OR from 0.4 for the percutaneous route to 0.2 for the pulmonary route); at the patient level, the male gender (OR = 1.3), the age of 15 years or more (OR = 1.9), and the absence of a long-term condition (OR = 1.3); at the physician level, the reception of a public healthcare insurance representative (OR = 4.1), the nonreception of pharmaceutical sales representatives (OR = 3.0), and the urban practice environment (OR = 2.8). In 2015, less than one third of drugs were prescribed in INN only in general practice. The use of various incentives and regulatory measures is likely to favor the prescription of INNs by practitioners.

Identifiants

pubmed: 30368571
doi: 10.1007/s00228-018-2580-8
pii: 10.1007/s00228-018-2580-8
doi:

Substances chimiques

Drugs, Generic 0
Prescription Drugs 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

275-283

Références

Expert Opin Drug Saf. 2004 May;3(3):167-72
pubmed: 15155145
Med J Malaysia. 2008 Oct;63(4):315-8
pubmed: 19385492
Health Policy. 2011 Feb;99(2):139-48
pubmed: 20732723
J Am Med Inform Assoc. 2010 Nov-Dec;17(6):681-8
pubmed: 20962131
Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):185-91
pubmed: 21254290
Health Policy. 2012 Mar;104(3):247-52
pubmed: 22217861
BMC Pharmacol Toxicol. 2013 Jan 05;14:1
pubmed: 23289757
Indian J Pharmacol. 2013 May-Jun;45(3):252-7
pubmed: 23833368
Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):469-82
pubmed: 23977975
Int J Med Inform. 2014 Jan;83(1):47-56
pubmed: 24168761
J Pharm Pharm Sci. 2013;16(4):511-29
pubmed: 24210060
J Rural Health. 2014 Summer;30(3):235-43
pubmed: 24528129
PLoS One. 2014 Oct 03;9(10):e104828
pubmed: 25279555
BMC Med Educ. 2016 Apr 27;16:126
pubmed: 27117188
JAMA Intern Med. 2016 Jun 1;176(6):763-8
pubmed: 27159336
Pharmacoepidemiol Drug Saf. 2017 Jul;26(7):819-826
pubmed: 28485111
Intern Med J. 2017 Aug;47(8):959-962
pubmed: 28782212
BMJ Open. 2017 Sep 27;7(9):e016408
pubmed: 28963287
Pediatr Infect Dis J. 1996 Jan;15(1):18-22
pubmed: 8684871

Auteurs

Florent De Bruyne (F)

Collège universitaire de médecine générale, Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Etienne, F-42023, Saint-Etienne, France.

Arnaud Ponçon (A)

Collège universitaire de médecine générale, Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Etienne, F-42023, Saint-Etienne, France.

Joris Giai (J)

Université Lyon 1, F-69622, Villeurbanne, France.
Laboratoire de Biométrie et Biologie Évolutive, CNRS, UMR5558, F-69622, Villeurbanne, France.
Service de Biostatistique, Hospices Civils de Lyon, F-69003, Lyon, France.

Xavier Dode (X)

Département de Pharmacie, Hospices Civils de Lyon, Lyon, France.

David Darmon (D)

Département d'Enseignement et de Recherche en Médecine Générale, Université de Nice Sophia-Antipolis, Nice, France.
UMR 912 Sesstim Inserm, Marseille, France.

Cyrille Colin (C)

Université Lyon 1, F-69622, Villeurbanne, France.
Health Services and Performance Research, HESPER EA 7425, Lyon Cedex 3, France.
Pôle IMER des Hospices Civils de Lyon, Lyon, France.

François Gueyffier (F)

Service de Pharmaco-Toxicologie, Hospices Civils de Lyon, 69000, Lyon, France.
UMR 5558, CNRS & Université Claude Bernard Lyon 1, 69000, Lyon, France.

Laurent Letrilliart (L)

Collège universitaire de médecine générale, Univ. Lyon, Université Claude Bernard Lyon 1, Université Saint-Etienne, F-42023, Saint-Etienne, France. laurent.letrilliart@univ-lyon1.fr.
Health Services and Performance Research, HESPER EA 7425, Lyon Cedex 3, France. laurent.letrilliart@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH